BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26482622)

  • 1. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
    Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
    Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.
    Chen MJ; Lin PL; Wang L; Cheng YM; Chen CY; Lee H
    Thorac Cancer; 2020 Jul; 11(7):1904-1910. PubMed ID: 32394538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
    Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
    Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
    Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
    Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
    Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
    Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of filamin-A protein is associated with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.
    Gachechiladze M; Skarda J; Janikova M; Mgebrishvili G; Kharaishvili G; Kolek V; Grygarkova I; Klein J; Poprachova A; Arabuli M; Kolar Z
    Neoplasma; 2016; 63(2):274-81. PubMed ID: 26774150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
    Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
    Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
    Tian FM; Zhong CY; Wang XN; Meng Y
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
    Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
    Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
    Oshita F; Kameda Y; Nishio K; Tanaka G; Yamada K; Nomura I; Nakayama H; Noda K
    Oncol Rep; 2000; 7(3):491-5. PubMed ID: 10767357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of altered eIF3a and its association with p27 in non-small cell lung cancers.
    Shen J; Yin JY; Li XP; Liu ZQ; Wang Y; Chen J; Qu J; Xu XJ; McLeod HL; He YJ; Xia K; Jia YW; Zhou HH
    PLoS One; 2014; 9(4):e96008. PubMed ID: 24789280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
    Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
    Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.